Education Information

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Academic allergists including training program and division directors
  • Allergy/immunology fellows in training
  • Physician assistants and advanced practice nurses
  • Allied health professionals
  • Primary care physicians and other medical professionals

Overall Educational Objectives

At the conclusion of this activity, participants should be able to:

  • Identify major advances in key areas of cutting-edge research in immunologic mechanisms and allergic responses.
  • Demonstrate knowledge of basic processes linking molecular and cellular biology and genetics with allergic pathophysiology and immunodeficiency.
  • Translate emerging clinical science principles to clinical practice in patients with allergic and immunologic diseases.
  • Evaluate and implement state-of-the-art diagnostic and therapeutic strategies for treating patients with allergic and immunologic diseases.
  • Explain the impact of environmental exposures and external influences on patients with allergic disorders.
  • Recognize emerging trends in the prevalence of allergic and immunologic disorders and discuss their impact on public health.
  • Evaluate the impact of new diagnostic and therapeutic strategies on health care costs and outcomes.
  • Discuss processes, tools and technologies for the efficient allergy and immunology practice.

Disclosure Statement

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
 
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.
 

Accreditation Statements

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 30.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This continuing medical education activity has been reviewed by the American Academy of Pediatrics and is acceptable for a maximum of 30.25 AAP credits. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the American Academy of Pediatrics.

Advanced Practice Health Care Providers
One-Day Course:
This activity has been designated for up to 6 Continuing Education contact hours.

Allied Health Professionals
One-Day Course:
This activity has been designated for up to 6 Continuing Education contact hours.
 

Maintenance of Certification

ACAAI will not be designating any 2022 Annual Meeting sessions for MOC Part II Self-Assessment Credit. However, you’ll find other opportunities to earn MOC Part II Self-Assessment credit on the College Learning Connection (education.acaai.org).

IMPORTANT: ABAI’s MOC program requires diplomates to obtain a minimum of 25 CME credits in allergy and immunology each year. CME credits for the Annual Meeting can be used to satisfy this requirement.

Back to Top